In this video, health-care analyst David Williamson walks investors through today's Aveo Pharmaceuticals (NASDAQ:AVEO) bloodbath. Shares are down 50% as an FDA advisory committee voted overwhelmingly against its drug candidate tivozanib. Find out why the decision shook out like it did, and if Aveo is a bad news buy after today's extreme plunge.